<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The DOK1 gene is a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene located on the human chromosome 2p13 which is frequently rearranged in <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and other human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously reported that the DOK1 gene can be mutated and its expression down-regulated in human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the mechanism underlying DOK1 silencing remains largely unknown </plain></SENT>
<SENT sid="3" pm="."><plain>We show here that unscheduled silencing of DOK1 expression through aberrant hypermethylation is a frequent event in a variety of human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>DOK1 was found to be silenced in nine <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> (<z:chebi fb="170" ids="36856">HNC</z:chebi>) cell lines studied and DOK1 CpG hypermethylation correlated with loss of gene expression in these cells </plain></SENT>
<SENT sid="5" pm="."><plain>DOK1 expression could be restored via demethylating treatment using <z:chebi fb="0" ids="50131">5-aza-2'deoxycytidine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, transduction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines with DOK1 impaired their proliferation, consistent with the critical role of epigenetic silencing of DOK1 in the development and maintenance of malignant cells </plain></SENT>
<SENT sid="7" pm="."><plain>We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human <z:hpo ids='HP_0002664'>neoplasm</z:hpo> including <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> (93% in <z:chebi fb="170" ids="36856">HNC</z:chebi>, 81% in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>) and haematopoietic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (64% in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>Control blood samples and exfoliated mouth epithelial cells from healthy individuals showed a low level of DOK1 methylation, suggesting that DOK1 hypermethylation is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> specific event </plain></SENT>
<SENT sid="9" pm="."><plain>Finally, an inverse correlation was observed between the level of DOK1 gene methylation and its expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and adjacent non <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissues </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, hypermethylation of DOK1 is a potentially critical event in human <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, and may be a potential <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biomarker and an attractive target for epigenetic-based therapy </plain></SENT>
</text></document>